IL17A and metabolic syndrome: In addition, systemic inflammation and pro-inflammatory IL-17 signalling were shown to persist at the end of treatment in psoriasis patients with metabolic syndrome, reducing the length of remission and resulting in earlier relapse compared to psoriasis patients without metabolic syndrome [35].